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Abstract
Introduction—Using National HIV surveillance system data we estimated life expectancy and 
average years of life lost among person diagnosed with HIV infection during 2008–2011.
Methods—Population-based surveillance data, restricted to persons with diagnosed HIV 
infection age 13 years or older, from all 50 states and D.C. were used to estimate life expectancy 
after HIV diagnosis using the life table method. Generated estimates were compared with life 
expectancy in the general population in the same calendar year to calculate average years of life 
lost (AYLL). Life expectancy and average years of life lost were also estimated for subgroups by 
age, sex and race/ethnicity.
Results—The overall life expectancy after HIV diagnosis in the United States, increased 3.43 
years from 25.43 (95% Confidence interval (CI) 25.37–25.49) in 2008, to 28.86 (95% CI 28.80–
28.92) in 2011.
Improvements were observed irrespective of sex, race/ethnicity, transmission category and stage of 
disease at diagnosis, though the extent of improvement varied by different characteristics. Based 
on the life expectancy in the general population, in 2010 the AYLL, were 12.8 years for males and 
16.5 years for females. By race/ethnicity, on average blacks (13.3 years) and whites (13.4 years) 
had fewer AYLL than Hispanic/Latinos (14.7).
Conclusions—Despite improvements in life expectancy among people diagnosed with an HIV 
infection during 2008–2011, disparities by sex and by race/ethnicity persist. Targeted efforts 
should continue to further reduce disparities and improve life expectancy after HIV diagnosis.
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Introduction
Introduction of highly active antiretroviral therapy (HAART) in the mid-1990s brought 
significant improvement in survival of people living with diagnosed human 
immunodeficiency virus (HIV) infection (PLWDH). Previous estimates of survival or life 
expectancy after HIV diagnosis showed an increase from 10.5 years in 1996 to 22.5 years, in 
20051 among people who were diagnosed with an HIV infection during that period. As 
treatments have evolved further, it is plausible that life expectancy after an HIV diagnosis 
has improved since the last estimates. Survival and life expectancy are also important 
measures to determine disparities in HIV care and treatment outcomes, and contribute to 
monitoring national objectives to reduce disparities and HIV-related mortality set by 
National HIV/AIDS Strategy and the Healthy people 20202,3. Another quantitative measure 
of changes in life expectancy is the average years of life lost (AYLL), after a change in 
health status, such as diagnosis of a disease. The AYLL (also called potential years of life 
lost) is an estimate of the number of years of life ‘lost’ because of premature mortality 
occurring in a person with a certain health condition. At the population level, in HIV’s 
context, AYLL represent the average number of additional years a person living with 
diagnosed HIV would have lived if that person had not died prematurely4. The knowledge of 
AYLL can be useful in drafting legislation and resource allocation, and serve as a measure of 
an individual’s disease burden for improving planning for clinical care5.
While some estimates of mortality and life expectancy are available6-11, the studies were 
either done outside of the United States or on a subset of PLWDH, such as those receiving 
care at a particular health care facility, and therefore did not represent large population-based 
estimates of life expectancy. The only large surveillance-data based estimates of life 
expectancy available from the United States 1 covered PLWDH, with HIV diagnosed by year 
2005 and included data from only 25 states. With advancements in treatment and the 
potential impact on life expectancy following HIV diagnosis, these estimates need to be 
updated with new and more recent data representing the entire country.
We used National HIV Surveillance System (NHSS) data from all 50 states and Washington 
D.C. to estimate the life expectancy among people who were diagnosed with an HIV 
infection during 2008– 2011. We also estimated AYLL in the year 2010 by comparing the 
life expectancy estimates generated by our analysis with the life expectancy of the general 
U.S. population for that year.
Methods
As part of NHSS, all states and the District of Columbia have reported cases of acquired 
immunodeficiency syndrome (AIDS) to the Centers for Disease Control and Prevention 
(CDC) since the early 1980s. Starting in 1994, jurisdictions that adopted confidential name-
based HIV surveillance started reported cases of HIV infection to CDC. By April of 2008, 
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all 50 states and District of Columbia had implemented confidential name-based HIV 
surveillance. In this analysis, NHSS data from entire country were used to estimate the life 
expectancy after HIV diagnosis among adults and adolescents (≥ 13 years of age) during 
2008–2011. All data reported to the CDC through June 2013 were used. This allowed for a 
minimum period of 18 month for reporting of deaths occurring by the end of 2011. All 
deaths, irrespective of cause, among people with diagnosed HIV infection were included in 
this analysis and data were adjusted for reporting delays and missing risk factors 12,13.
Following National Center for Health Statistics’ (NCHS) approach, we modeled life 
expectancy after HIV diagnosis, using the period life table method 14 that is based on the 
mortality experience of a hypothetical cohort and assumes that the age-specific death rates 
remain unchanged in future years. This means that persons who will be in a given age 
bracket in the future will experience the same age-specific death rates as the one experienced 
by persons currently in that age bracket. We used an exponential model for estimating age-
specific death rates, in which the death rates within one year after diagnosis of HIV and 
deaths rates more than one year after diagnosis were estimated separately, because the death 
rates in the two time periods are quite different 15.
We estimated overall life expectancy in each of the four years of diagnosis (2008–2011) as 
well as by selected characteristics of interest that included sex at birth, race/ethnicity, HIV 
stage at diagnosis and HIV transmission category. Race/ethnicity was categorized into four 
categories; black/African American (hereafter referred to as black), Hispanic/Latino, white 
and ‘other races’ representing a cumulative category for all minority races/ethnicities other 
than blacks and Hispanics/Latinos. HIV stage at diagnosis was categorized into two 
categories; stage 3 [AIDS] vs. other that included persons whose stage at diagnosis was 
unknown. We also estimated life expectancy separately for males and females by the four 
HIV transmission categories among males [male-to-male sexual contact, injection-drug use 
(IDU), male-to-male sexual contact and IDU, and heterosexual contact), and by two 
transmission categories among females (IDU and heterosexual contact].
We estimated AYLL by sex and by the age at HIV diagnosis, by subtracting the estimated 
life expectancy of the person with an HIV diagnosis from the life expectancy of an 
individual of the same age and sex, in the general population in 2010, using NCHS vital 
statistics data for 2010 14.
Results
In the four years from 2008 to 2011, an estimated total of 184,749 persons were diagnosed 
with HIV in the United States. The total number of diagnoses each year decreased from 
2008 through 2011. This decrease was also observed across both sexes, most races/
ethnicities, and by stage of disease at diagnosis. However, the distribution of diagnoses by 
sex, race/ethnicity and stage at diagnosis remained similar across the years. By transmission 
category, a similar decline was observed except among males with infection attributed to 
male-to-male sexual contact [hereafter referred to as men who have sex with men (MSM)], 
which showed a slight increase (<2%) in numbers from 2008 to 2011 (Table 1).
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In the four-year period from 2008 to 2011, the overall average life expectancy after HIV 
diagnosis in the United States, increased 3.43 years from 25.43 (95% Confidence interval 
(CI) 25.37–25.49) in 2008, to 28.86 (95% CI 28.80–28.92) in 2011, representing a 13.5% 
increase over the four year period with an average and fairly steady increase of about 4.5% 
per year. Life expectancy in each of the 4 years represented a statistically significant increase 
from the previous year, as determined by the non-overlapping 95% CIs. Although 
improvements were observed in both sexes, the life expectancy was better for males as 
compared to females. In each year from 2008 to 2011, males generally had higher life 
expectancy than females and also experienced a larger increase in life expectancy (3.64 
years) compared with females (2.64 years). Persons with late-stage disease at diagnosis 
(stage 3 [AIDS] had a life expectancy that was on average 6.6 years lower than that for 
persons with HIV not classified as stage 3. This pattern and the magnitude of difference 
were consistent across all 4 years (table 2).
By race/ethnicity, Hispanics/Latinos had a longer life expectancy than any other race/
ethnicity throughout 2008–2011 (table 2). The lowest life expectancy in 2008 was observed 
in blacks (23.68), whereas ‘other races’ (minorities other than blacks and Hispanics/
Latinos), had the lowest life expectancy in years 2009–2011. The largest difference between 
any two races/ethnicities was observed in 2010, when Hispanics/Latinos had a life 
expectancy 5 years longer than ‘other races’. The difference between life expectancies of 
Hispanics/Latinos and blacks that was 4.59 years in 2008 shrank steadily over the four-year 
period to 2.34 years in 2011. When comparing whites with blacks similar shrinking of 
difference, with eventual reversal was observed. In the year 2008, whites experienced 2.02 
years longer life expectancy than blacks. However, this difference consistently reduced in 
the following years to 0.46 years in 2010 and eventually reversed to 0.68 years favoring 
blacks (table 2). While all races/ethnicities experienced an improvement in life expectancy 
2008–2011, blacks experienced the largest gain (4.78 years), followed by Hispanics/Latinos 
(2.52 years), whites (2.08 years) and other races (1.42 years). Percent wise, blacks’ life 
expectancy increased by 20.2%, Hispanics/Latinos 8.9%, whites 8.1% and other races 5.8% 
(Table 2).
By transmission category, among males, in each year from 2008 to 2010, the longest life 
expectancy was observed among MSM, followed by males with infection attributed to male-
to-male sexual contact and IDU, heterosexual contact, and finally IDU (table 2). In 2011, 
life expectancy of MSM (32.30, 95% CI 32.22–32.39) was 12.06 years (60%) higher than 
the life expectancy of males with infection attributed to IDU (20.24, 95% CI 20.0–20.48). 
Among females, in each of the four years life expectancy was higher among those with 
infection attributed to heterosexual contact compared with those with infection attributed to 
IDU. In 2011, females with infection attributed to heterosexual contact had a life expectancy 
of 27.90, 95% CI 27.75–28.05 vs. 21.36, 95% CI 21.08–21.64, among females who inject 
drugs. This represents a 6.54 years (31%) higher life expectancy in females with infection 
attributed to heterosexual contact, compared with females whose HIV infection was 
attributed to IDU. Persons in all transmission categories and both sexes experienced 
significant increases in life expectancy from 2008 to 2011. Percent wise, from 2008 to 2011, 
the largest (14.2%, 2.66 years) and smallest (7.6%, 1.96 years) increases were among 
females with infection attributed to IDU and heterosexual contact, respectively. Among 
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males, increases of 13.4% (2.39 years), 12.8% (3.00 years), 12.7% (2.65 years) and 10.2% 
(3.00 years) were observed in males with infection attributed to IDU, male-to-male sexual 
contact and IDU, heterosexual contact, and male-to-male sexual contact, respectively (Table 
2).
Although overall, females had lower life expectancy than males, when limited to either 
injection-drug use or heterosexual contact, the life expectancy among females was longer 
than that among males. Females who injected drugs had 1-2 years longer life expectancy 
than males who injected drugs, while the life expectancy among females with HIV infection 
attributed to heterosexual contact was about 4-5 years longer than males with infection 
attributed to heterosexual contact.
Using the life expectancy in the general population by age, sex and race as reference, in 
2010 the AYLL were 12.80 years for males and 16.53 years for females. At ages, 20, 40, 60 
and 80 years, males who were diagnosed with an HIV infection in 2010, had AYLL of 
17.57, 14.14, 10.35 and 6.16 years respectively. For females diagnosed with HIV infection 
in 2010, at ages 20,40, 60 and 80 years the AYLL were 24.53, 18.29, 12.08 and 7.31 years 
respectively. By race/ethnicity, on average blacks (13.26 years) and whites (13.43 years) had 
fewer AYLL than Hispanic/Latinos (14.72). Life expectancy along with AYLL, among 
persons diagnosed with HIV infection in year 2010 at five-year age intervals and sex are 
presented in table 3. Estimated AYLL at age at diagnosis in 2010, by sex and by race/
ethnicity are graphically presented in figures 1 and 2 respectively.
Discussion
The life expectancy of people who were diagnosed with an HIV infection during 2008–2011 
presented in this paper represents the first estimates using data from all 50 U.S. states and 
the District of Columbia (D.C.). The results show that the life expectancy improved over the 
four-year interval 2008– 2011 for all populations from 25.43 years in 2008 to 28.86 years in 
2011, representing an increase in life expectancy of 3.43 years or 13.5%. While similar life 
expectancy estimates have been reported by other studies in the era of HAART 9,16, the 
direct comparison of results is difficult, as the published estimates in contemporary literature 
show large variation because of varying methodologies, time spans studied, and populations 
of interest. Our results also indicate that during 2008–2011, the life expectancy for persons 
diagnosed with HIV infection has continued to improve since the publication of last 
estimates using more limited HIV surveillance data from 25 states, that compared pre- and 
post-HAART eras 1.
MSM consistently had longer life expectancy than persons with HIV infection attributed to 
any other transmission category and on average expected to live more than a decade longer 
than persons with HIV infection attributed to IDU; who in turn had a worse life expectancy 
than persons in any other transmission category, consistent with earlier findings 17. The high 
mortality among persons who inject drug may be due to other risk factors related to IDU that 
lead to premature mortality, such as cigarette smoking, comorbidities, drug overdose and 
barriers to accessing HIV care and medications . A recent study found that among a cohort 
of approximately 18,000 HIV-infected individuals, smokers suffered from higher mortality 
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than non-smokers (mortality rate ratio; 1.94, 95% CI 1.56–2.41) 18,19. Persons who inject 
drugs are also more likely to have other comorbidities, such as hepatitis-C infection and 
mental illnesses, and also face health-care access challenges 20-23. A study in New York City 
found that among HIV-HCV co-infected individuals, 60% had their infection attributed to 
injection drug use 22.
Additionally, the role of social determinants of health such as low education, high poverty, 
discrimination and low access to and poor retention in health care that negatively affect life 
expectancy cannot be ruled out 24-28. All these factors have been shown to have an 
association with IDU29-31
Life expectancy of females was lower than that of males, and since life expectancy of 
females in the general population is longer than that of males, the AYLLS for females in 
2010, were higher than for males at all ages at diagnosis. We found that in 2011 the life 
expectancy of younger females (<40 years at HIV diagnosis) was less than that of males that 
were the same age at HIV diagnosis. However this pattern reversed in older age groups, with 
females who were 40 years of age or older at HIV diagnosis, had slightly better life 
expectancy than men who were diagnosed at age 40 or older. Since men with infection 
attributed to male-to-male sexual contact have longer life expectancy than men with 
infection attributed to other causes and because a large proportion of HIV-infected MSM are 
diagnosed at a young age 32, it helps explain the better life expectancy seen among males in 
the younger age groups. This explanation is further supported by the fact that when 
comparisons across sex are made within the transmission categories common to both sexes, 
i.e., injection drug use and heterosexual contact, females have longer life expectancy than 
males (table 2).
Hispanics/Latinos had higher AYLL in 2010, than either blacks or whites, and the difference 
between Hispanics and whites, and Hispanics and blacks, increased slightly with increasing 
age at diagnosis until about age 50 and then reduced a little as age at diagnosis pushed into 
older years (Figure 2). Hispanics/Latinos are more likely to enter care late and are more 
likely to discontinue treatment than whites 33,34, which helps explain the higher AYLL 
among Hispanics/Latinos infected with HIV. Although life expectancy of blacks in the 
general population is slightly lower than that of whites, and blacks with diagnosed HIV have 
a higher rate of death than whites diagnosed with HIV, the life expectancy of the two groups 
was similar, with blacks showing a slightly longer life expectancy than whites in 2011. The 
apparent paradox is explained by the fact that HIV tends to be diagnosed at an earlier age in 
blacks as compared to whites. Indeed, among person diagnosed with HIV in 2011; among 
blacks 27.4% were diagnosed before reaching 25 years of age, and 53.4% were diagnosed 
before age 35. The percentages among whites were 13.6 and 39.8 respectively 35.
The results of these analyses can be a useful resource for clinicians as well as policy makers. 
They can guide patient-provider communications on prognoses and expectations after an 
HIV diagnosis; whereas policy makers may find these results to be a useful guide for 
estimating costs for care and resource allocation.
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Our estimates’ biggest strength is that they are based on data from the entire country with 
documented high completeness of reporting, instead of a sub-sample of states. However, 
there still are a few limitations of our analysis. Not all HIV diagnoses may have been 
included, as some states offer anonymous HIV testing, which are not reported to HIV 
surveillance. Additionally person who are HIV infected, but not yet diagnosed are also not 
included in the surveillance data. However these factors are unlikely to have a significant 
impact on our estimates as it has been estimated that HIV-infected, yet undiagnosed persons 
make up only about 12.8% of the total persons infected with HIV in the United Sates 36.
Another limitation of our estimates is that we did not take into account the influence of 
comorbidities, HIV treatment and viral load suppression status, all of which influence 
mortality and thus the life expectancy. Also, some deaths among persons with HIV may not 
yet have been reported to surveillance. Therefore our estimates could be an over or 
underestimate of the true life expectancy after HIV diagnosis. However, we do not expect 
any systematic association with any of the factors that can lead to net over- or under-
estimation of life expectancy. For this reason and because we used a very large dataset 
covering the entire country with high degree of completeness, we expect our estimates to be 
reliable estimates.
In summary, our analysis shows that the persons diagnosed with an HIV infection during 
2008–2011, experience better life expectancy than those diagnosed in previous years and 
that the life expectancy continued to improve during 2008–2011, with consequent reduction 
in AYLL, overall and across all sex, race and transmission categories. However, the life 
expectancy of PLWDH still remains shorter than the life expectancy of the general 
population of the United States. While further improvements in the life expectancy of HIV-
infected person is possible as treatment regimens continue to evolve, with improvements the 
role of other factors (e.g. early diagnosis, availability and access to treatment, adherence to 
treatment, side effects of antiretroviral therapy etc.) come to play a greater role in 
determining the period one can expect to live after an HIV diagnosis 37-40. Our analysis 
demonstrates that the life expectancy after HIV diagnosis has continued to improve in 
HAART era. As the proportion of persons living with HIV who know their status (i.e. 
diagnosed) continue to increase and the access to HAART and adherence to treatment 
continue to improve, more accurate estimates should be generated in the future for continued 
monitoring of the progress of the status of the disease. Not all sub-groups show similar 
improvements in life expectancy, therefore individualized treatment plans, taking into 
consideration the actual needs and challenges of each subgroup can help improve life 
expectancy in these subgroups and reduce disparities.
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Estimated average years of life lost after HIV diagnosis in 2010, by sex, United States.
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Table 1
Estimated numbers of diagnoses of HIV infection among adults and adolescents, by selected characteristics, 
2008–2011, United States.
Year of diagnosis 2008 2009 2010 2011
Number of diagnoses1 49,061 46,403 44,931 44,354
Sex n (%) n (%) n (%) n (%)
    Male 37,154 (75.7) 35,794 (77.1) 35,045 (78.0) 35,011 (78.9)
    Female 11,908 (24.3) 10,610 (22.9) 9,886 (22.0) 9,343 (21.1)
Race/Ethnicity
    Black/African American 23,520 (47.9) 22,026 (47.5) 21,285 (47.4) 20,837 (47.0)
    Hispanic/Latino 9,633 (19.6) 9,356 (20.2) 9,065 (20.2) 9,198 (20.7)
    White 13,510 (27.5) 12,757 (27.5) 12,419 (27.6) 12,147 (27.4)
    Other races/ethnicities 2,400 (4.9) 2,264 (4.9) 2,162 (4.8) 2,172 (4.9)
Stage at diagnosis
    Stage 3 (within 3 months) 14,188 (28.9) 13,454 (29.0) 13,176 (29.3) 12,737 (28.7)
    Not stage 32 34,873 (71.1) 32,949 (71.0) 31,755 (70.7) 31,616 (71.3)
Transmission Category—Males
   Male-to-male sexual contact
   (MSM) 27,315 (73.5) 27,081 (75.7) 27,021 (77.1) 27,608 (78.9)
   Injection drug use
   (IDU) 2,993 (8.1) 2,542 (7.1) 2,265 (6.5) 1,991 (5.7)
   Male-to-male sexual contact
   and injection drug use (MSM-
   IDU)
1,720 (4.6) 1,546 (4.3) 1,465 (4.2) 1,291 (3.7)
      Heterosexual contact 5,073 (13.7) 4,572 (12.8) 4,241 (12.1) 4,068 (11.6)
Transmission Category—Females
   Injection drug use
   (IDU) 2,003 (16.8) 1,724 (16.2) 1,472 (14.9) 1,324 (14.2)
      Heterosexual contact 9,860 (82.8) 8,831 (83.2) 8,352 (84.5) 7,939 (85.0)
1
Totals include persons with HIV transmission attributed to infrequent causes such as hemophilia etc.
2
Includes stage unknown
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Table 2
Life expectancy of persons diagnosed with HIV infection by year of diagnosis, overall and by selected 
characteristics, 2008–2011, United States.
Year of diagnosis 2008 2009 2010 2011
Number of Diagnoses3 49,061 46,403 44,931 44,354
ELE (95% CI) 4 ELE (95% CI)2 ELE (95% CI) 2 ELE (95% CI) 2
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Totals include persons with HIV transmission attributed to infrequent causes such as hemophilia etc.
4
Estimated life expectancy and 95% confidence intervals.
5
Includes stage unknown
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Table 3
Estimated life expectancy and average years of life lost, among persons diagnosed with HIV infection in 2010, 
by sex and at age at diagnosis by 5 year intervals, United States.
Estimated Life Expectancy Average years of life lost
Age at Diagnosis (years) Male Female Male Female
15 43.62 40.70 18.28 25.90
20 39.53 37.17 17.57 24.53
25 35.55 33.74 16.85 23.16
30 31.69 30.43 16.11 21.57
35 27.96 27.22 15.14 19.98
40 24.36 24.11 14.14 18.29
45 20.89 21.08 13.01 16.62
50 17.54 18.12 12.06 15.08
55 14.30 15.21 11.10 13.59
60 11.15 12.32 10.35 12.08
65 8.12 9.42 9.58 10.88
70 5.53 6.54 8.67 9.96
75 3.52 4.15 7.48 8.75
80 2.04 2.39 6.16 7.31
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